Drug intelligence / Profile preview

ILB-323

Development stage: Preclinical
Lead developer: ILIAS Biologics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules

Overview

ILB-323 is a preclinical-stage drug candidate developed by ILIAS Biologics. It acts as an inhibitor of NF-κB, a key transcription factor involved in the regulation of inflammation and immune responses. The drug is being investigated for its potential to treat neuralgia and possibly other inflammatory or metabolic diseases. ILIAS Biologics specializes in exosome-based therapeutics, suggesting that ILB-323 may utilize exosome technology for delivery, although this has not been explicitly confirmed for this specific candidate[1][3].

Targets

NF-κB

Beyond the preview

Go deeper on ILB-323.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILB-323.

Explore the full profile